World Hypopara Awareness Day is June 1!
Join us in raising awareness for people living with hypoparathyroidism and share this link.

Advancing peptides for the treatment of rare endocrine and related diseases

We are a clinical stage, global company, building on our team’s established expertise to transform the lives of patients living with rare endocrine and related diseases.



Our lead clinical candidate is a potentially clinically superior therapeutic peptide in development for hypoparathyroidism.


AZP-3813 is a highly potent, peptide growth hormone (GH) receptor antagonist in development for acromegaly.

AZP-3813 Acromegal


Our management team has the collective and proven expertise necessary to advance its portfolio of therapeutic peptides in the clinic.

Press Releases & Recent News

Amolyt Pharma Announces Positive Safety and Efficacy Results from Second Patient Cohort in its Phase 2a Trial of AZP-3601 for the Treatment of Hypoparathyroidism

Download a PDF copy of this press release: EN FR 93% of patients in Cohort 2 discontinued both active vitamin …

Read More →
Download a PDF: EN or FR

Amolyt Pharma to Present Full Phase 2a Data on AZP-3601 at Upcoming Conferences

Download a PDF copy of this press release: EN FR Data from cohort 2 and full Phase 2a clinical trial …

Read More →
Download a PDF: EN or FR

Join Our Team

We are always looking for talented and driven individuals to join our diverse and collaborative team to help us achieve our mission.

Contact Us

We welcome open and continuous dialogue with all interested parties, including patients, healthcare providers, potential partners and investors.

Scroll to Top